Heterozygous carriers of a MMR gene alteration are at a greatly increased lifetime risk to develop cancers of the LS tumor spectrum, mainly CRC (25–70%) and endometrial cancer (30–70%) (12). Here, MRC1 is linked to colorectal carcinoma.